keyword
MENU ▼
Read by QxMD icon Read
search

Prostate MRI

keyword
https://www.readbyqxmd.com/read/29341356/all-over-the-map-an-interobserver-agreement-study-of-tumor-location-based-on-the-pi-radsv2-sector-map
#1
Matthew D Greer, Joanna H Shih, Tristan Barrett, Sandra Bednarova, Ismail Kabakus, Yan Mee Law, Haytham Shebel, Maria J Merino, Bradford J Wood, Peter A Pinto, Peter L Choyke, Baris Turkbey
BACKGROUND: Prostate imaging reporting and data system version 2 (PI-RADSv2) recommends a sector map for reporting findings of prostate cancer mulitparametric MRI (mpMRI). Anecdotally, radiologists may demonstrate inconsistent reproducibility with this map. PURPOSE: To evaluate interobserver agreement in defining prostate tumor location on mpMRI using the PI-RADSv2 sector map. STUDY TYPE: Retrospective. POPULATION: Thirty consecutive patients who underwent mpMRI between October, 2013 and March, 2015 and who subsequently underwent prostatectomy with whole-mount processing...
January 17, 2018: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29339663/evaluation-of-magnetic-resonance-imaging-ultrasound-fusion-biopsy-in-patients-with-low-risk-prostate-cancer-under-active-surveillance-undergoing-surveillance-biopsy
#2
Angelika Borkowetz, Theresa Renner, Ivan Platzek, Marieta Toma, Roman Herout, Martin Baunacke, Christer Groeben, Johannes Huber, Michael Laniado, Gustavo B Baretton, Michael Froehner, Stefan Zastrow, Manfred P Wirth
INTRODUCTION: Targeted biopsy of tumour-suspicious lesions detected in multiparametric magnetic resonance imaging (mpMRI) plays an increasing role in the active surveillance (AS) of patients with low-risk prostate cancer (PCa). The aim of this study was to compare MRI/ultrasound-fusion biopsy (fusPbx) with systematic biopsy (sysPbx) in patients undergoing biopsy for AS. METHODS: Patients undergoing mpMRI and transperineal fusPbx combined with transrectal sysPbx (comPbx) as surveillance biopsy were investigated...
January 16, 2018: Urologia Internationalis
https://www.readbyqxmd.com/read/29337128/-estimating-minimum-period-of-time-to-perform-prostate-mri-after-prostate-biopsy-clinical-and-histological-bleeding-risk-factors-from-a-prospective-study
#3
M Sarradin, C Lepiney, O Celhay, P O Delpech, T Charles, P Pillot, S Bernardeau, J P Tasu, J Irani
A minimum delay of 4 to 6 weeks between biopsy and multiparametric prostatic MRI (mpMRI) is admitted due to post-biopsy hemorrhage that can impact MRI reading without strong scientific evidence. The objective of the study was to evaluate the best period between prostate biopsy and 3Tesla mpMRI and searching for predictive factors of intraprostatic blood. A prostate biopsy followed by a 4-week prostate MRI (MRIp M1) was performed. In case of hemorrhage, MRI was rescheduled at 8 and 12 weeks (M2/M3). We analyzed the persistant bleeding to identify risk factors: anticoagulant/antiaggregant, post-biopsy side effects, histological criteria...
January 11, 2018: Progrès en Urologie
https://www.readbyqxmd.com/read/29336979/prostate-magnetic-resonance-imaging-the-truth-lies-in-the-eye-of-the-beholder
#4
Joseph C Riney, Nabeel E Sarwani, Shehzad Siddique, Jay D Raman
PURPOSE: To determine the diagnostic accuracy and interobserver variability of radiologic interpretation of magnetic resonance imaging (MRI) performed for surgical planning before prostatectomy. PATIENTS AND METHODS: The records of 233 men undergoing prostatectomy with presurgical multiparametric 3T surface body coil MRI were reviewed. All initial films were read by a fellowship-trained body radiologist provided with relevant clinical information. A senior radiologist then reread all pelvic MRIs blinded to the initial interpretation with findings from both readings compared to final pathology...
January 11, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29336835/standard-whole-prostate-gland-radiotherapy-with-and-without-lesion-boost-in-prostate-cancer-toxicity-in-the-flame-randomized-controlled-trial
#5
Evelyn M Monninkhof, Juliette W L van Loon, Marco van Vulpen, Linda G W Kerkmeijer, Floris J Pos, Karin Haustermans, Laura van den Bergh, Sofie Isebaert, Gill M McColl, Robert Jan Smeenk, Juus Noteboom, Iris Walraven, Petra H M Peeters, Uulke A van der Heide
PURPOSE: To compare toxicity rates in patients with localized prostate cancer treated with standard fractionated external beam radiotherapy (EBRT) with or without an additional integrated boost to the macroscopically visible tumour. MATERIAL AND METHODS: FLAME is a phase 3 multicentre RCT (NCT01168479) of patients with pathologically confirmed localized intermediate or high-risk prostate cancer. The standard treatment arm (n = 287) received a dose to the entire prostate of 77 Gy in 35 fractions...
January 11, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/29333958/focal-mri-guided-salvage-high-dose-rate-brachytherapy-in-patients-with-radiorecurrent-prostate-cancer
#6
Metha Maenhout, Max Peters, Marco van Vulpen, Marinus A Moerland, Richard P Meijer, Maurice A A J van den Bosch, Paul L Nguyen, Steven J Frank, Jochem R N van der Voort van Zyp
INTRODUCTION: Whole-gland salvage treatment of radiorecurrent prostate cancer has a high rate of severe toxicity. The standard of care in case of a biochemical recurrence is androgen deprivation treatment, which is associated with morbidity and negative effects on quality of life. A salvage treatment with acceptable toxicity might postpone the start of androgen deprivation treatment, might have a positive influence on the patients' quality of life, and might even be curative. Here, toxicity and biochemical outcome are described after magnetic resonance imaging-guided focal salvage high-dose-rate brachytherapy in patients with radiorecurrent prostate cancer...
December 2017: Technology in Cancer Research & Treatment
https://www.readbyqxmd.com/read/29331622/value-of-serial-multiparametric-magnetic-resonance-imaging-and-magnetic-resonance-imaging-guided-biopsies-in-men-with-low-risk-prostate-cancer-on-active-surveillance-after-1-yr-follow-up
#7
Esther Hendrika Johanna Hamoen, Caroline M A Hoeks, Diederik M Somford, Inge M van Oort, Henk Vergunst, Jorg R Oddens, Geert A Smits, Leonard P Bokhorst, J Alfred Witjes, Maroeska M Rovers, Christina A Hulsbergen-van de Kaa, Jelle O Barentsz
BACKGROUND: Active surveillance (AS) aims to reduce overtreatment of low-risk prostate cancer (PC). Incorporating multiparametric magnetic resonance imaging (mp-MRI) and MR-guided biopsy (MRGB) in an AS protocol might contribute to more accurate identification of AS candidates. OBJECTIVE: To evaluate the value of 3T mp-MRI and MRGB in PC patients on AS at inclusion and after 12-mo follow-up. DESIGN, SETTING, AND PARTICIPANTS: Patients with cT1c-cT2 PC, prostate-specific antigen (PSA) ≤10ng/ml, PSA density <0...
January 10, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29331575/validation-of-mri-to-trus-registration-for-high-dose-rate-prostate-brachytherapy
#8
Eric Poulin, Karim Boudam, Csaba Pinter, Samuel Kadoury, Andras Lasso, Gabor Fichtinger, Cynthia Ménard
PURPOSE: The objective of this study was to develop and validate an open-source module for MRI to transrectal ultrasound (TRUS) registration to support tumor-targeted prostate brachytherapy. METHODS AND MATERIALS: In this study, 15 patients with prostate cancer lesions visible on multiparametric MRI were selected for the validation. T2-weighted images with 1-mm isotropic voxel size and diffusion weighted images were acquired on a 1.5T Siemens imager. Three-dimensional (3D) TRUS images with 0...
January 10, 2018: Brachytherapy
https://www.readbyqxmd.com/read/29331524/strategies-and-technical-challenges-for-imaging-oligometastatic-disease-recommendations-from-the-european-organisation-for-research-and-treatment-of-cancer-imaging-group
#9
REVIEW
Nandita M deSouza, Yan Liu, Arturo Chiti, Daniela Oprea-Lager, Géraldine Gebhart, Bernard E Van Beers, Ken Herrmann, Frederic E Lecouvet
Patients with oligometastatic disease (OMD) often have controllable symptoms, and cures are possible. Technical improvements in surgery and radiotherapy have introduced the option of metastasis-directed ablative therapies as an adjunct or alternative to standard-of-care systemic therapies. Several clinical trials and registries are investigating the benefit of these therapeutic approaches across several cancer sites. This requires that patients are correctly included and followed with appropriate imaging. This article discusses the evidence and offers recommendations for the implementation of standard-of-care (Response Evaluation Criteria in Solid Tumours measurements on computed tomography [CT], magnetic resonance imaging [MRI] and bone scintigraphy) and advanced imaging modalities (functional, metabolic and radionuclide targeted) for identifying and following up patients with OMD...
January 10, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29331081/quantitative-fe-mri-determination-of-the-dynamics-of-psma-targeted-spions-discriminates-among-prostate-tumor-xenografts-based-on-their-psma-expression
#10
Laurel O Sillerud
BACKGROUND: There is a need for a quantitative MRI method for iron concentration magnetic resonance imaging suitable for measuring the delivery of targeted superparamagnetic iron oxide nanoparticles (SPIONs) to tumors. PURPOSE: To apply our newly developed [Fe]MRI method to the quantitative imaging in both space and time of the iron dynamics of anti-prostate specific membrane antigen (PSMA) conjugated SPIONs within human prostate tumor xenografts in nude mice. STUDY TYPE: Longitudinal...
January 13, 2018: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29326030/patient-reported-outcomes-following-abiraterone-acetate-plus-prednisone-added-to-androgen-deprivation-therapy-in-patients-with-newly-diagnosed-metastatic-castration-naive-prostate-cancer-latitude-an-international-randomised-phase-3-trial
#11
Kim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, Gaetano Facchini, Henrik Suttman, Nobuaki Matsubara, Zhangqun Ye, Bhumsuk Keam, Ronaldo Damião, Tracy Li, Kelly McQuarrie, Bin Jia, Peter De Porre, Jason Martin, Mary B Todd, Karim Fizazi
BACKGROUND: In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study...
January 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29325321/-preliminary-applicability-evaluation-of-prostate-imaging-reporting-and-data-system-version-2-diagnostic-score-in-3-0t-multi-parameters-magnetic-resonance-imaging-combined-with-prostate-specific-antigen-density-for-prostate-cancer
#12
M Z Zuo, W L Zhao, C G Wei, C Y Zhang, R Wen, Y F Gu, M J Li, Y Y Zhang, J F Wu, X Li, J K Shen
Objective: To investigate the preliminary applicability of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) score in the condition of 3.0T multi-parametric magnetic resonance imaging (Mp-MRI) combined with clinical classic indicators for the diagnosis of prostate cancer (PCa). Methods: The clinical and MRI materials of 247 patients of suspicious prostate disease treated in Second Affiliated Hospital of Soochow University from June 2015 to November 2016 were analyzed retrospectively, including 110 cases with PCa and 137 cases without cancer...
December 19, 2017: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/29324926/risk-stratification-and-staging-in-prostate-cancer-with-prostatic-specific-membrane-antigen-pet-ctobjective-a-one-stop-shop
#13
Manoj Gupta, Partha Sarathi Choudhury, Sudhir Rawal, Harish Chandra Goel, Amitabh Singh, Vineet Talwar, Saroj Kumar Sahoo
OBJECTIVE: Current imaging modalities for prostate cancer (PC) had limitations for risk stratification and staging. Magnetic resonance imaging (MRI) frequently underestimated lymphatic metastasis while bone scintigraphy often had diagnostic dilemmas. Prostatic specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET/CT) has been remarkable in diagnosing PC recurrence and staging. We hypothesized it can become one-stop-shop for initial risk stratification and staging...
September 2017: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29323548/18f-fluorocholine-pet-whole-body-mri-in-the-staging-of-high-risk-prostate-cancer
#14
Ur Metser, Alejandro Berlin, Jaydeep Halankar, Grainne Murphy, Kartik S Jhaveri, Sangeet Ghai, Noam Tau
OBJECTIVE: The purpose of this study was to determine whether integrated 18F-fluorocholine (FCH) PET whole-body MRI (PET/WBMRI) depicts lymph node and distant metastases in patients with high-risk prostate cancer more frequently than does conventional staging. SUBJECTS AND METHODS: A prospective study included 58 patients with untreated high-risk prostate cancer. After conventional staging (CT and bone scintigraphy), patients underwent FCH PET/WBMRI (n = 10) or FCH PET/CT and WBMRI (n = 48)...
January 11, 2018: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/29318440/correction-to-mri-us-fusion-guided-biopsy-performing-exclusively-targeted-biopsies-for-the-early-detection-of-prostate-cancer
#15
Maurizio Del Monte, Costantino Leonardo, Vincenzo Salvo, Marcello Domenico Grompone, Martina Pecoraro, Arnaldo Stanzione, Riccardo Campa, Francesco Vullo, Alessandro Sciarra, Carlo Catalano, Valeria Panebianco
In the original publication of the article, the first and last names of the second author were interchanged.
January 9, 2018: La Radiologia Medica
https://www.readbyqxmd.com/read/29317377/multiparametric-mri-for-the-detection-of-local-recurrence-of-prostate-cancer-in-the-setting-of-biochemical-recurrence-after-low-dose-rate-brachytherapy
#16
Luca F Valle, Matthew D Greer, Joanna H Shih, Tristan Barrett, Yan Mee Law, Andrew B Rosenkrantz, Haytham Shebel, Akhil Muthigi, Daniel Su, Maria J Merino, Bradford J Wood, Peter A Pinto, Andra V Krauze, Aradhana Kaushal, Peter L Choyke, Barış Türkbey, Deborah E Citrin
PURPOSE: Prostate multiparametric magnetic resonance imaging (mpMRI) has utility in detecting post-radiotherapy local recurrence. We conducted a multireader study to evaluate the diagnostic performance of mpMRI for local recurrence after low dose rate (LDR) brachytherapy. METHODS: A total of 19 patients with biochemical recurrence after LDR brachytherapy underwent 3T endorectal coil mpMRI with T2-weighted imaging, dynamic contrast-enhanced imaging (DCE) and diffusion-weighted imaging (DWI) with pathologic confirmation...
January 2018: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
https://www.readbyqxmd.com/read/29315957/apparent-diffusion-coefficients-in-prostate-cancer-correlation-with-molecular-markers-ki-67-hif-1%C3%AE-and-vegf
#17
Teng Ma, Shaolin Yang, Haiyan Jing, Lin Cong, Zhixin Cao, Zhiling Liu, Zhaoqin Huang
Prostate cancer (PCa) is the second most common cancer in men. The Gleason score (GS) and biomarkers play important roles in the diagnosis and treatment of patients with PCa. The purpose of this study was to investigate the relationship between the apparent diffusion coefficient (ADC) and the molecular markers Ki-67, hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) in PCa. Thirty-nine patients with 39 lesions, who had been diagnosed with PCa, were enrolled in this study. All patients underwent diffusion-weighted magnetic resonance imaging (DW-MRI) (b = 800 s/mm2 )...
January 9, 2018: NMR in Biomedicine
https://www.readbyqxmd.com/read/29313360/diagnostic-bone-imaging-in-patients-with-prostate-cancer-patient-experience-and-acceptance-of-naf-pet-ct-choline-pet-ct-whole-body-mri-and-bone-spect-ct
#18
Eva Dyrberg, Emil L Larsen, Helle W Hendel, Henrik S Thomsen
Background Patient acceptance is an important factor when implementing imaging methods in clinical practice in line with availability, diagnostic accuracy, and cost-effectiveness. Purpose To investigate patient experience and acceptance regarding18F-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT), 11 C-choline-PET/CT, whole-body magnetic resonance imaging (WB-MRI), and 99mTc-hydroxymethane diphosphonate (HDP) single photon emission/computed tomography (SPECT/CT). Material and Methods One hundred and forty-nine patients with prostate cancer filled in a questionnaire regarding their experience of the imaging procedures they had been undergoing as part of a diagnostic accuracy study...
January 1, 2018: Acta Radiologica
https://www.readbyqxmd.com/read/29308912/in-bore-mri-guided-biopsy-can-it-optimize-the-need-for-periodic-biopsies-in-prostate-cancer-patients-undergoing-active-surveillance-a-pilot-test-retest-reliability-study
#19
Kareem K Elfatairy, Christopher P Filson, Martin G Sanda, Adeboye O Osunkoya, Rachel L Geller, Sherif G Nour
OBJECTIVE: To evaluate the test-retest reliability of repeated in-bore MRI-guided prostate biopsy (MRGB). METHODS: Nineteen lesions in 7 patients who had consecutive MRGBs were retrospectively analyzed. Three patients had only 2 consecutive MRGBs and two patients had 3 consecutive MRGBs. Both multiparametric MRI and MRGBs were performed using a 3T MRI scanner. Pathology results were categorized into benign, suspicious and malignant. Consistency between 1st and subsequent biopsy results were analyzed as well as the negative predictive value (NPV) for prostate cancer...
January 8, 2018: British Journal of Radiology
https://www.readbyqxmd.com/read/29307684/development-of-a-nationally-representative-coordinated-registry-network-for-prostate-ablation-technologies
#20
Ron Golan, Adrien Bernstein, Art Sedrakyan, Timothy J Daskivich, Dongyi T Du, Behfar Ehdaie, Benjamin Fisher, Michael A Gorin, Ivan Grunberger, Bradley Hunt, Hongying H Jiang, Hyung L Kim, Danica Marinac-Dabic, Leonard S Marks, Timothy D McClure, Jeffrey S Montgomery, Dipen J Parekh, Sanoj Punnen, Stephen Scionti, Charles J Viviano, John T Wei, Sven Wenske, James S Wysock, John Rewcastle, Mark Carol, Marc Oczachowski, Jim C Hu
BACKGROUND: The accumulation of data through a prospective, multi-center coordinated registry network (CRN) is a practical way to gather real world evidence on the performance of novel prostate ablation technologies. Urologic oncologists, targeted biopsy experts, industry representatives, and the Food and Drug Administration (FDA) convened to discuss the role, feasibility, and important data elements of a CRN to assess new and existing prostate ablation technologies. METHODS: A multi-round Delphi consensus approach was performed which included the opinion of 15 expert urologists, representatives of the FDA and leadership from HIFU device manufacturers...
January 4, 2018: Journal of Urology
keyword
keyword
7558
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"